Aquila Biopharmaceuticals Inc Profile last edited on: 8/1/08
CAGE:
UEI:
Business Identifier: NO Business Identifier is currently available for this company. 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
3 Forbes Road
Lexington, MA 02421
Lexington, MA 02421
| N/A |
| N/A |
| N/A |
Location: Single
Congr. District: 05
County: Middlesex
Congr. District: 05
County: Middlesex
Public Profile
In November 2000 Antigenics Inc. (Nasdaq: AGEN) of New York acquired Aquila Biopharmaceuticals, Inc. (Nasdaq: AQLA). Antigenics is working to develop personalized immunotherapeutics and revolutionary treatments for cancers, infectious diseases and autoimmune disorders. The companyâs lead product candidate is Oncophage, a late-stage, personalized cancer vaccine being evaluated in several indications, including renal cell carcinoma and metastatic melanom
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
150-249Revenue Range
15M-20MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2001 | 1 | NIH | $302,541 | |
| Project Title: A P. Falciparum MSP1 p42/QS-21 Malaria Vaccine | ||||
| 2000 | 1 | NIH | $100,000 | |
| Project Title: Lipid-Based Vaccines For Staphylococcus Aureus | ||||
| 2000 | 1 | NIH | $127,989 | |
| Project Title: CD1 Presented Vaccines to Prevent Chlamydia Infection | ||||
Key People / Management
Gerald A Beltz
Sandra P Chang
Sandra P Chang
Company News
There are no news available.
